CM
BLUE

Crestline Management’s bluebird bio BLUE Stock Holding History

Crestline Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,251
Closed -$2.54M – 158
2018
Q2 		$2.54M Buy
+1,251
New +$2.85M 0.27% 108
2017
Q4 		– Sell
-972
Closed -$1.73M – 163
2017
Q3 		$1.73M Buy
972
+211
+28% +$295K 0.24% 77
2017
Q2 		$1.04M Buy
+761
New +$918K 0.14% 87

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Crestline Management's BLUE Position: Q3 2018 in Review

Crestline Management sold out of bluebird bio (BLUE) in Q3 2018, closing a stake of 1,251 shares — an estimated $2.54M sold.

Crestline Management first reported a position in BLUE in Q2 2017 and held it in 3 quarters. The position peaked at $2.54M in Q2 2018. 288 funds tracked by Wall St. Rank hold BLUE as of Q3 2018.

  • Crestline Management reported no remaining bluebird bio position as of Q3 2018 after selling out during the quarter.
  • Crestline Management sold 1,251 bluebird bio shares in Q3 2018, an estimated $2.54M.
  • Crestline Management first reported a position in bluebird bio in Q2 2017 and held it in 3 quarters.
  • Crestline Management's bluebird bio position peaked at $2.54M in Q2 2018.
  • 288 funds tracked by Wall St. Rank held bluebird bio as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.